Owlet Q1 2026: Owlet360 Subscriptions Shine While the Ledger Keeps a Lower-Profile Glow

Overview: a subscription-led quarter with a telehealth edge

Owlet, Inc. reported its first quarter of 2026 results on a revenue beat-and-balance-sheet basis that underscores a pivot toward a higher‑margin, subscription-driven model, anchored by its Owlet360 service. The company disclosed revenue of $22.5 million for the quarter, up 6.4% year over year, with Owlet360 subscribers climbing to more than 115,000 paying as of March 31. A side thread is the company’s OnCall pediatric telehealth launch, positioned to bolster customer lifetime value as care moves deeper into at‑home platforms.

In the press release, management highlighted a shift toward higher value opportunities, emphasizing a strategy to scale the pediatric health platform while sharpening operating efficiency. The narrative centers on turning subscriber momentum into durable revenue, even as the bottom line remains pressured by ongoing investment and non‑GAAP adjustments.

Financial snapshot

• Revenue: $22.5 million for Q1 2026; up from $21.1 million in Q1 2025.
• Revenue mix: Subscription revenue was $2.7 million in the quarter.
• Gross margin: 54.5%, up 80 basis points year over year (driven by Owlet360 growth, favorable product mix, and lower direct/fulfillment costs; tariff impacts offset some gains).
• Cost of revenue: $10.2 million for the quarter.
• Operating expenses: $17.7 million, up from $14.0 million a year earlier, with headcount and stock-based compensation contributing to the year‑over‑year increase.
• Operating loss: $5.5 million for Q1 2026 (vs. $2.7 million in Q1 2025).
• Net loss: $3.3 million for Q1 2026 (versus net income of $3.0 million in Q1 2025).
• Adjusted EBITDA (non-GAAP): $(1.5) million for Q1 2026 (vs. $0.0 million in Q1 2025).
• EPS: Net loss per share of $(0.15); Adjusted net loss per share (non-GAAP) of $(0.09).

The release notes that the year‑over‑year operating expense rise is largely due to staffing, stock-based compensation, and related salary/benefits costs. The gross margin expansion, while modest, came despite tariff pressures, suggesting mix effects from Owlet360 and better cost discipline in fulfillment.

What the leadership said

“I am reassuming the CEO role to build on the mission I started 12 years ago, with a clear, long-term mandate to lead Owlet through its next phase of scale and development in pediatric health,” said Kurt Workman, Owlet’s President, CEO, and Co‑Founder.

Workman added that the company is evolving into a comprehensive pediatric health and data platform, with Owlet360 already scaling and the official release of OnCall as a key milestone intended to broaden access to care while extending customer relationships.

“Looking ahead, we are concentrating our resources to capture the significant white space in our high‑value markets,” he continued, signaling a deliberate plan to translate product bets into durable growth and institutional value.

Outlook and strategic signal

The company notes an updated financial outlook for 2026, though the released excerpt stops short of enumerating specific targets. The phrasing suggests a pivot toward emphasizing the long‑term trajectory of Owlet360 subscriptions, platform data monetization, and telehealth capabilities as a core growth vector. In the near term, investors will likely watch for how revenue forecast revisions align with subscriber growth, and whether the trajectory implies a path toward improved gross margin leverage as the subscription base scales.

Implications for Owlet and peers in the sector

The quarterly narrative is less about a one-off earnings surprise and more about a structural shift: a consumer electronics company layering in health data services and telehealth. If Owlet can convert subscriber momentum into repeat revenue through Owlet360 and the OnCall offering, the model could attract capital keen on recurring revenue streams in pediatric care.

For sector peers, the message is twofold. First, subscriptions and data-enabled services can meaningfully lift gross margins if scale mitigates fulfillment costs. Second, the regulatory and reimbursement environment around at‑home health services remains a critical variable; telehealth platforms that can demonstrate clear value to families and insurers may unlock durable demand. Analysts will weigh against EPS consensus and the public market’s tolerance for near-term losses as investments in growth continue.

In the broader market, this quarter reinforces a trend: investors are less impressed by a single quarter and more enticed by multi‑quarter momentum in at‑home health platforms, consumer health data, and subscription engines that promise longer customer lifetimes. If Owlet’s strategy manages to bend the cost curve while expanding ARR (annual recurring revenue), it could set a competitive bar for peers dabbling in pediatric health tech and consumer medical devices.

Bottom line

Owlet’s Q1 2026 results emphasize a company navigating growth with a subscription‑first approach, anchored by Owlet360 and the launch of OnCall. Revenue growth is modest but real; gross margin gains exist, though operating losses persist as investments in people and products persist. The key unknown is the size and timing of the updated 2026 outlook and how investors interpret the EPS trajectory in light of non‑GAAP adjustments.

For peers, the takeaway is clear: build durable, recurring relationships in pediatric health, monetize through data-enabled services, and keep a steady eye on the cost of growth. The next several quarters will test whether Owlet can translate subscriber momentum into a sustainable earnings path, or whether the market will demand a longer runway before meaningful profitability arrives.